UBS analyst Dan Leonard initiated coverage of Bio-Techne with a Buy rating and $80 price target. The analyst sees a path for Bio-Techne to return to double-digit growth post the “COVID hangover.” The firm says the company’s core protein reagents business has high-single digit growth prospects. Growth drivers in instruments as well as potential upsides in cell therapy should solidly restore Bio-Techne’s double-digit sales trend, contends UBS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TECH:
- Bio-Techne price target lowered to $66 from $90 at Wells Fargo
- Early notable gainers among liquid option names on November 7th
- Biotech Alert: Searches spiking for these stocks today
- Bio-Techne price target lowered to $70 from $100 at Deutsche Bank
- Bio-Techne price target lowered to $68 from $90 at Baird
